Unless there is strong price erosion in the abilify, company expects to maintain current EBIDTA margins Company expects at least 2 new entrants in the time to come. However, if there are new entrants, prices may fall further. Torrent will have to adapt to the new environment to maintain its position.Ībilify the prices have stabilized considering current players in the market. However, large companies like Torrent are at advantage because of the long standing and deep relationships and good product portfolio. In US market the channel consolidation is not good for the Indian companies as there are only 4 large Customers and hence they do ask for competitive prices. This model of collaborations with R&D companies will continue as it will allow company to leverage its strong commercial and marketing skills 3 of the products collaborated are soft gel products. They are entering into 9 collaborations for R&D projects with outside companies to fill the gap for capabilities of the company and fast track the filings. Current is not a part of Gland acquisition. We need to diversify from oral solid retail to hospital presence. 400 scientists hiring was started in Q1 FY16.Ĭapex- 1500cr for 2-3 years including maintenance capex.Īcquisition- 300-600mn USD range but we can even do larger acquisition. Indian R&D will also go up- First in India pdts and first in the world, innovative delivery forms (similar to 505B2 in US) for all divisions CMS, CVS, GI etc. Absolute value terms also it will be higher. We will like to maintain it at that level going fwd as well. R&D expenses outlook- FY16 was 4% of sales, 250cr. Hopefully 2018 onwards Brazil may show growth. Between 2015-2020 things have changed…macro issues. Its not what it was but it is still a good market. Capacity constraints getting solved slowly due to freeing up of capacity at Indrad.īrazil volume growth 8%. 4 large customersĮurope grew 10% cc…large part is Germany. ex-abilify base business gone up in a good way. Other products maybe better so wont increase Nexium capacity at expense other products.īase business of US- 0.5bn sales can be sustainable in next 2-3 years. Pricing is not that great with 6-7 player market. 5-7% market share guidance due to complexity of manufacturing. Nexium- Slow ramp up as brand is still occupying 44% share. 4 player market…share can go up in coming months. Dahej will free capacity for Germany, Brazil, UK, Romania in next 2 years.ĭetrol LA- Torrent had 15% share in March. As pdts get ramped up we will supply 180-200cr tablets from Dahej. By next year we will have 10 approvals from Dahej. 3 prdt approvals (site transfers) happened from Dahej. Abilify Sales decline can be partially offset by scale up of other products from Dahej for US business. Market share as per IMS (March) 4% and actual number is higher. Price erosion happened for Abilify and will continue. Balance 9 launches- most of them will be before end of calendar year. 15-20 ANDAs will be approved next year.įY17 will have 10 launches of USD 9bn= 6bn Crestor+ others 3bn.Ĭrestor will be competitive and Torrent will not be in wave 1. 2-3 minor 483 observations were product specific.Īctive projects- 121, 9 externals projects compared to 40-50 last year. It went well and we hope to get EIR in a few months. Indrad inspection was a product specific inspection….2 products. Launched 5 products in US in FY16…Transferred one product from Sun Ranbaxy Price increase on Elder portfolio have been taken in end of Q3. Inventory days have come down from 79 to 62? Low growth in Q4 due to reduction in inventories. Sales force productivity focus…increased 30% MR strength 2720. FDC ban on alternatives to Chymoral may benefit Torrent. India formulations- low exposure to regulations. Biosimilars business off to a rocking start with 2 launches.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |